BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11794961)

  • 1. [From the physiopathology of thrombosis to therapeutic targets].
    Nurden P; Ndoko S; Nurden AT
    Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1210-7. PubMed ID: 11794961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines.
    Hostetter JC; Bhatt DL
    Minerva Cardioangiol; 2003 Oct; 51(5):531-46. PubMed ID: 14551522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet agents and arterial thrombosis.
    Billett HH
    Clin Geriatr Med; 2006 Feb; 22(1):57-74, viii. PubMed ID: 16377467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Konstantopoulos K; Mousa SA
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in pharmacotherapy of thrombosis.
    Labuzek K; Krysiak R; Okopien B; Herman ZS
    Pol J Pharmacol; 2003; 55(4):523-33. PubMed ID: 14581710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.
    Marcus AJ; Broekman MJ; Drosopoulos JH; Olson KE; Islam N; Pinsky DJ; Levi R
    Semin Thromb Hemost; 2005 Apr; 31(2):234-46. PubMed ID: 15852226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects.
    Choi J; Kermode JC
    Mol Interv; 2011 Apr; 11(2):111-23. PubMed ID: 21540471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of platelets in atherothrombosis.
    Jennings LK
    Am J Cardiol; 2009 Feb; 103(3 Suppl):4A-10A. PubMed ID: 19166707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet function testing and implications for clinical practice.
    Collet JP; Montalescot G
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The anti-platelet aggregation drugs: new approaches based on snake venom polypeptides].
    Marrakchi N; Guermazi S; El Ayeb M
    Arch Inst Pasteur Tunis; 1997; 74(1-2):9-15. PubMed ID: 15945171
    [No Abstract]   [Full Text] [Related]  

  • 18. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
    Wilson JM; Ferguson JJ
    Clin Cardiol; 1999 Nov; 22(11):687-98. PubMed ID: 10554682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events.
    Levy Y; Shenkman B; Tamarin I; Pauzner R; Shoenfeld Y; Langevitz P; Savion N; Varon D
    Arthritis Rheum; 2005 Dec; 52(12):4011-7. PubMed ID: 16320349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.